| Targeting DnaN for tuberculosis therapy using novel griselimycins A Kling, P Lukat, DV Almeida, A Bauer, E Fontaine, S Sordello, ... Science 348 (6239), 1106-1112, 2015 | 357 | 2015 |
| Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates … KA Cohen, T Abeel, A Manson McGuire, CA Desjardins, V Munsamy, ... PLoS medicine 12 (9), e1001880, 2015 | 320 | 2015 |
| Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis E Nuermberger, S Tyagi, R Tasneen, KN Williams, D Almeida, I Rosenthal, ... Antimicrobial agents and chemotherapy 52 (4), 1522-1524, 2008 | 244 | 2008 |
| Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis D Almeida, T Ioerger, S Tyagi, SY Li, K Mdluli, K Andries, J Grosset, ... Antimicrobial agents and chemotherapy 60 (8), 4590-4599, 2016 | 222 | 2016 |
| Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance CA Desjardins, KA Cohen, V Munsamy, T Abeel, K Maharaj, BJ Walker, ... Nature genetics 48 (5), 544-551, 2016 | 202 | 2016 |
| Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor S Gupta, S Tyagi, DV Almeida, MC Maiga, NC Ammerman, WR Bishai American journal of respiratory and critical care medicine 188 (5), 600-607, 2013 | 198 | 2013 |
| Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis IM Rosenthal, R Tasneen, CA Peloquin, M Zhang, D Almeida, KE Mdluli, ... Antimicrobial agents and chemotherapy 56 (8), 4331-4340, 2012 | 173 | 2012 |
| Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis E Nuermberger, I Rosenthal, S Tyagi, KN Williams, D Almeida, ... Antimicrobial agents and chemotherapy 50 (8), 2621-2625, 2006 | 165 | 2006 |
| Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice JH Grosset, S Tyagi, DV Almeida, PJ Converse, SY Li, NC Ammerman, ... American journal of respiratory and critical care medicine 188 (5), 608-612, 2013 | 145 | 2013 |
| Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis S Tyagi, NC Ammerman, SY Li, J Adamson, PJ Converse, RV Swanson, ... Proceedings of the National Academy of Sciences 112 (3), 869-874, 2015 | 144 | 2015 |
| Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention D Almeida, C Rodrigues, ZF Udwadia, A Lalvani, GD Gothi, P Mehta, ... Clinical infectious diseases 36 (12), e152-e154, 2003 | 130 | 2003 |
| Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis RV Swanson, J Adamson, C Moodley, B Ngcobo, NC Ammerman, ... Antimicrobial agents and chemotherapy 59 (6), 3042-3051, 2015 | 109 | 2015 |
| Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis D Almeida, E Nuermberger, R Tasneen, I Rosenthal, S Tyagi, K Williams, ... Antimicrobial agents and chemotherapy 53 (10), 4178-4184, 2009 | 107 | 2009 |
| Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis J Xu, SY Li, DV Almeida, R Tasneen, K Barnes-Boyle, PJ Converse, ... Antimicrobial agents and chemotherapy 63 (5), 10.1128/aac. 00021-19, 2019 | 94 | 2019 |
| High Incidence of the Beijing Genotype among Multidrug-Resistant Isolates of Mycobacterium tuberculosis in a Tertiary Care Center in Mumbai, India D Almeida, C Rodrigues, TF Ashavaid, A Lalvani, ZF Udwadia, A Mehta Clinical infectious diseases 40 (6), 881-886, 2005 | 91 | 2005 |
| Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? PJ Converse, EL Nuermberger, DV Almeida, JH Grosset Future Microbiology 6 (10), 1185-1198, 2011 | 79 | 2011 |
| Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering BM Lee, LK Harold, DV Almeida, L Afriat-Jurnou, HL Aung, BM Forde, ... PLoS pathogens 16 (2), e1008287, 2020 | 77 | 2020 |
| Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? IM Rosenthal, M Zhang, D Almeida, JH Grosset, EL Nuermberger American journal of respiratory and critical care medicine 178 (9), 989-993, 2008 | 75 | 2008 |
| Pharmacokinetics of Rifampin and Clarithromycin in Patients Treated for Mycobacterium ulcerans Infection JWC Alffenaar, WA Nienhuis, F De Velde, AT Zuur, AMA Wessels, ... Antimicrobial agents and chemotherapy 54 (9), 3878-3883, 2010 | 69 | 2010 |
| Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo NC Ammerman, RV Swanson, A Tapley, C Moodley, B Ngcobo, ... Journal of Antimicrobial Chemotherapy, dkw417, 2016 | 65 | 2016 |
